Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced today that its Arrow Seldinger Arterial Catheterization Device received market clearance from the U.S. Food and Drug Administration (FDA).
The new Arrow Seldinger Arterial Catheterization Device is indicated for short-term use. The device is designed to improve patient safety by eliminating confusion of catheter identification, reduce risk of complications associated with insertion technique, and provide optimal diagnostics leading to effective treatment for patients. Multiple sizes are available to provide customization to each patient, each insertion site, and each application.
“As we continue to discover new and innovative solutions, the Seldinger Arterial Catheterization Device is now part of our extensive arterial offering in the U.S. market,” said Jake Newman, Vice President and General Manager of Teleflex’s Vascular Access Division. “This innovative device is intended to facilitate ease of insertion and resistance to body collapse1.”
Teleflex expects to launch the Arrow® Seldinger Arterial Catheterization Device in the United States this year.
n our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
1. Teleflex. Seldinger Arterial Catheter Benchtop Studies. Data on File, D011453: 2014.